Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tension-Type Headache | 20 | 2023 | 77 | 7.720 |
Why?
|
Migraine Disorders | 30 | 2024 | 1620 | 5.620 |
Why?
|
Headache | 22 | 2024 | 1226 | 2.480 |
Why?
|
Headache Disorders | 5 | 2023 | 130 | 1.960 |
Why?
|
Pain Threshold | 11 | 2023 | 584 | 1.570 |
Why?
|
Post-Traumatic Headache | 7 | 2023 | 74 | 1.240 |
Why?
|
Neck Pain | 5 | 2023 | 180 | 1.040 |
Why?
|
Hyperalgesia | 4 | 2023 | 502 | 0.990 |
Why?
|
Headache Disorders, Secondary | 1 | 2023 | 36 | 0.870 |
Why?
|
Calcitonin Gene-Related Peptide | 3 | 2020 | 306 | 0.790 |
Why?
|
Vertigo | 1 | 2020 | 202 | 0.640 |
Why?
|
Pain Perception | 2 | 2017 | 191 | 0.610 |
Why?
|
Dizziness | 1 | 2020 | 251 | 0.600 |
Why?
|
Cluster Headache | 1 | 2017 | 54 | 0.580 |
Why?
|
Central Nervous System Agents | 1 | 2017 | 72 | 0.580 |
Why?
|
Pain, Intractable | 1 | 2016 | 130 | 0.540 |
Why?
|
Analgesics | 5 | 2021 | 1040 | 0.540 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2016 | 449 | 0.480 |
Why?
|
Botulinum Toxins, Type A | 3 | 2022 | 213 | 0.460 |
Why?
|
Sensory System Agents | 1 | 2012 | 23 | 0.430 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2020 | 4266 | 0.430 |
Why?
|
Cortical Spreading Depression | 3 | 2021 | 276 | 0.430 |
Why?
|
Neuralgia, Postherpetic | 1 | 2012 | 38 | 0.420 |
Why?
|
Capsaicin | 1 | 2012 | 231 | 0.390 |
Why?
|
International Classification of Diseases | 1 | 2016 | 867 | 0.390 |
Why?
|
Depressive Disorder, Major | 2 | 2021 | 4644 | 0.390 |
Why?
|
Trigeminal Neuralgia | 1 | 2012 | 113 | 0.390 |
Why?
|
Ketamine | 1 | 2016 | 500 | 0.380 |
Why?
|
Epilepsy | 2 | 2023 | 3310 | 0.370 |
Why?
|
Brain Concussion | 4 | 2022 | 1320 | 0.350 |
Why?
|
Low Back Pain | 1 | 2018 | 956 | 0.340 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2010 | 131 | 0.330 |
Why?
|
Spinal Puncture | 1 | 2010 | 281 | 0.320 |
Why?
|
Self Report | 3 | 2022 | 3558 | 0.320 |
Why?
|
Pain Measurement | 5 | 2016 | 3420 | 0.320 |
Why?
|
Tryptamines | 3 | 2022 | 88 | 0.290 |
Why?
|
Moyamoya Disease | 1 | 2009 | 238 | 0.290 |
Why?
|
Humans | 66 | 2024 | 744343 | 0.270 |
Why?
|
Antibodies, Monoclonal | 3 | 2023 | 9274 | 0.270 |
Why?
|
Serotonin Receptor Agonists | 1 | 2006 | 152 | 0.260 |
Why?
|
Amitriptyline | 2 | 2010 | 110 | 0.260 |
Why?
|
Nociceptors | 4 | 2021 | 432 | 0.250 |
Why?
|
Muscle, Skeletal | 5 | 2015 | 4931 | 0.240 |
Why?
|
Mastocytosis, Systemic | 1 | 2005 | 100 | 0.230 |
Why?
|
Population Surveillance | 1 | 2014 | 2616 | 0.230 |
Why?
|
Vascular Headaches | 1 | 2023 | 22 | 0.220 |
Why?
|
Serotonin | 2 | 2005 | 1017 | 0.220 |
Why?
|
Vasoconstrictor Agents | 1 | 2006 | 642 | 0.210 |
Why?
|
Serotonin 5-HT1 Receptor Agonists | 1 | 2022 | 43 | 0.210 |
Why?
|
Quality of Life | 6 | 2024 | 12804 | 0.200 |
Why?
|
Migraine without Aura | 2 | 2013 | 83 | 0.190 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2004 | 365 | 0.190 |
Why?
|
Whiplash Injuries | 1 | 2020 | 15 | 0.190 |
Why?
|
Nausea | 1 | 2023 | 673 | 0.180 |
Why?
|
Intracranial Hypotension | 2 | 2010 | 41 | 0.180 |
Why?
|
Prevalence | 8 | 2023 | 15226 | 0.180 |
Why?
|
Migraine with Aura | 2 | 2013 | 203 | 0.170 |
Why?
|
Depressive Disorder | 1 | 2012 | 3748 | 0.170 |
Why?
|
Chronic Disease | 6 | 2016 | 9146 | 0.170 |
Why?
|
Treatment Outcome | 10 | 2023 | 63114 | 0.170 |
Why?
|
Vagus Nerve Stimulation | 1 | 2022 | 199 | 0.160 |
Why?
|
Headache Disorders, Primary | 1 | 2018 | 36 | 0.160 |
Why?
|
Comorbidity | 5 | 2018 | 10388 | 0.160 |
Why?
|
Meninges | 1 | 2019 | 190 | 0.160 |
Why?
|
Cross-Sectional Studies | 6 | 2023 | 25043 | 0.150 |
Why?
|
Neuromuscular Agents | 1 | 2019 | 134 | 0.150 |
Why?
|
Adult | 23 | 2024 | 214055 | 0.150 |
Why?
|
Female | 28 | 2024 | 380194 | 0.150 |
Why?
|
Double-Blind Method | 5 | 2023 | 12026 | 0.150 |
Why?
|
Middle Aged | 19 | 2021 | 213383 | 0.140 |
Why?
|
Neuralgia | 1 | 2022 | 570 | 0.130 |
Why?
|
Middle Cerebral Artery | 1 | 2017 | 264 | 0.130 |
Why?
|
Longitudinal Studies | 4 | 2022 | 13989 | 0.130 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2019 | 2282 | 0.120 |
Why?
|
Relaxation Therapy | 1 | 2015 | 178 | 0.120 |
Why?
|
Pain | 4 | 2022 | 4986 | 0.120 |
Why?
|
Male | 22 | 2022 | 350118 | 0.120 |
Why?
|
Continuity of Patient Care | 1 | 2021 | 1049 | 0.120 |
Why?
|
Blood Flow Velocity | 1 | 2017 | 1423 | 0.110 |
Why?
|
Skin | 2 | 2008 | 4364 | 0.110 |
Why?
|
Infusions, Intravenous | 1 | 2016 | 2274 | 0.100 |
Why?
|
Referral and Consultation | 2 | 2022 | 3528 | 0.100 |
Why?
|
Brain Infarction | 1 | 2013 | 299 | 0.100 |
Why?
|
Risk Factors | 8 | 2020 | 72290 | 0.100 |
Why?
|
Geriatric Assessment | 1 | 2018 | 1372 | 0.090 |
Why?
|
Cerebrospinal Fluid Pressure | 1 | 2010 | 35 | 0.090 |
Why?
|
Leukoencephalopathies | 1 | 2013 | 238 | 0.090 |
Why?
|
Administration, Topical | 1 | 2012 | 690 | 0.090 |
Why?
|
Subarachnoid Space | 1 | 2010 | 79 | 0.090 |
Why?
|
Prospective Studies | 4 | 2023 | 53288 | 0.090 |
Why?
|
Post-Dural Puncture Headache | 1 | 2010 | 49 | 0.090 |
Why?
|
Photophobia | 1 | 2009 | 67 | 0.090 |
Why?
|
Electric Stimulation | 2 | 2005 | 1767 | 0.080 |
Why?
|
Health Policy | 1 | 2021 | 2661 | 0.080 |
Why?
|
Biomedical Research | 1 | 2023 | 3309 | 0.080 |
Why?
|
Mianserin | 1 | 2007 | 52 | 0.070 |
Why?
|
Temporomandibular Joint Disorders | 1 | 2010 | 215 | 0.070 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2007 | 174 | 0.070 |
Why?
|
Telemedicine | 1 | 2024 | 2872 | 0.070 |
Why?
|
Aged | 7 | 2021 | 163280 | 0.070 |
Why?
|
Self Medication | 1 | 2006 | 117 | 0.070 |
Why?
|
Myofascial Pain Syndromes | 1 | 2005 | 35 | 0.070 |
Why?
|
Ibuprofen | 1 | 2007 | 236 | 0.060 |
Why?
|
Rats, Sprague-Dawley | 3 | 2021 | 8301 | 0.060 |
Why?
|
Incidence | 1 | 2023 | 20947 | 0.060 |
Why?
|
Primary Health Care | 1 | 2021 | 4558 | 0.060 |
Why?
|
Severity of Illness Index | 4 | 2012 | 15540 | 0.060 |
Why?
|
Cohort Studies | 3 | 2023 | 40561 | 0.060 |
Why?
|
Denmark | 1 | 2006 | 738 | 0.060 |
Why?
|
Cerebral Angiography | 1 | 2009 | 1285 | 0.060 |
Why?
|
Physical Stimulation | 1 | 2005 | 525 | 0.060 |
Why?
|
Adolescent | 5 | 2021 | 85781 | 0.060 |
Why?
|
Diagnosis, Differential | 2 | 2010 | 12959 | 0.050 |
Why?
|
Disabled Persons | 2 | 2022 | 1212 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 7181 | 0.050 |
Why?
|
Citalopram | 1 | 2004 | 403 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 9959 | 0.050 |
Why?
|
Drug Combinations | 1 | 2006 | 1959 | 0.050 |
Why?
|
Young Adult | 3 | 2021 | 56430 | 0.050 |
Why?
|
Logistic Models | 2 | 2012 | 13408 | 0.050 |
Why?
|
Leg | 1 | 2005 | 1116 | 0.040 |
Why?
|
Neuropeptides | 1 | 2005 | 942 | 0.040 |
Why?
|
Ketorolac | 1 | 2020 | 79 | 0.040 |
Why?
|
Rats | 3 | 2021 | 24260 | 0.040 |
Why?
|
Head | 1 | 2005 | 880 | 0.040 |
Why?
|
Nerve Fibers, Unmyelinated | 1 | 2019 | 98 | 0.040 |
Why?
|
Dilatation | 1 | 2020 | 291 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15076 | 0.040 |
Why?
|
Rodentia | 1 | 2020 | 261 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2004 | 2029 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2019 | 77449 | 0.040 |
Why?
|
Child | 2 | 2020 | 77709 | 0.040 |
Why?
|
United States | 4 | 2023 | 69872 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2003 | 2971 | 0.040 |
Why?
|
Statistics, Nonparametric | 1 | 2003 | 2886 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2007 | 6489 | 0.040 |
Why?
|
Macrophage Activation | 1 | 2020 | 558 | 0.040 |
Why?
|
Disability Evaluation | 1 | 2024 | 1827 | 0.030 |
Why?
|
Ultrasonography, Doppler, Transcranial | 1 | 2017 | 292 | 0.030 |
Why?
|
Blood-Brain Barrier | 1 | 2021 | 1017 | 0.030 |
Why?
|
Arteries | 1 | 2020 | 1119 | 0.030 |
Why?
|
Body Mass Index | 1 | 2012 | 12720 | 0.030 |
Why?
|
Animals | 4 | 2021 | 168757 | 0.030 |
Why?
|
Forecasting | 1 | 2003 | 2951 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2019 | 35421 | 0.030 |
Why?
|
Cost of Illness | 1 | 2024 | 1859 | 0.030 |
Why?
|
Nerve Block | 1 | 2020 | 644 | 0.030 |
Why?
|
Blood Platelets | 1 | 2004 | 2508 | 0.030 |
Why?
|
Dexamethasone | 1 | 2020 | 1951 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2014 | 39050 | 0.030 |
Why?
|
Prognosis | 3 | 2010 | 29063 | 0.030 |
Why?
|
Piperidines | 1 | 2020 | 1602 | 0.030 |
Why?
|
Pain, Postoperative | 1 | 2020 | 1643 | 0.020 |
Why?
|
Gene Expression | 1 | 2022 | 7799 | 0.020 |
Why?
|
Developing Countries | 1 | 2021 | 2815 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2005 | 7279 | 0.020 |
Why?
|
Hospitals | 1 | 2021 | 3952 | 0.020 |
Why?
|
Nitric Oxide Synthase | 1 | 2010 | 916 | 0.020 |
Why?
|
Iatrogenic Disease | 1 | 2010 | 547 | 0.020 |
Why?
|
Cerebrovascular Circulation | 1 | 2017 | 2731 | 0.020 |
Why?
|
Brain | 1 | 2013 | 26385 | 0.020 |
Why?
|
Patient Readmission | 1 | 2020 | 3114 | 0.020 |
Why?
|
Disease Progression | 2 | 2015 | 13284 | 0.020 |
Why?
|
Electric Stimulation Therapy | 1 | 2010 | 605 | 0.020 |
Why?
|
Cognition | 1 | 2021 | 6770 | 0.010 |
Why?
|
Random Allocation | 1 | 2008 | 2429 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3674 | 0.010 |
Why?
|
Sensory Receptor Cells | 1 | 2008 | 492 | 0.010 |
Why?
|
Early Diagnosis | 1 | 2008 | 1184 | 0.010 |
Why?
|
Inflammation | 1 | 2022 | 10638 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16365 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 21827 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10262 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8388 | 0.010 |
Why?
|
Treatment Failure | 1 | 2007 | 2618 | 0.010 |
Why?
|
Regression Analysis | 1 | 2008 | 6459 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2008 | 2716 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2007 | 10943 | 0.010 |
Why?
|
Sex Factors | 1 | 2008 | 10397 | 0.010 |
Why?
|
Mice | 1 | 2020 | 81183 | 0.010 |
Why?
|
Depression | 1 | 2008 | 7766 | 0.010 |
Why?
|
Concepts
(181)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(21)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_